Dangerous & wrong narrative being promulgated by ISPOR “Continued reliance on .. OS benefit as the primary measure of innovation in oncology ….restrict(s) patient access to innovative therapies & leads to higher healthcare costs”.
For details: Click here
Source: Richard Sullivan/Twitter